Pharmaceuticals News and Research

RSS

Preclinical studies shows EmPAC more effective than Taxol

Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone’s proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi’s sarcoma.

19 Sep 2011

Revolution in drug discovery underway in West Midlands, UK

A revolution in the drug discovery industry is underway, with universities across the West Midlands leading the effort by working in partnership with industry to focus on improving patient care.

19 Sep 2011

Too many kids poisoned with prescription drugs: Study

Figures show that each year half a million kids age 5 and younger get into household medications and are poisoned. Though parents tend to believe that these tragic accidents will never happen to their kids, Dr. Randall Bond, a leading advocate for better prescription drug safety in the home, believes it can happen to anyone.

19 Sep 2011

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects.

19 Sep 2011

Amneal announces availability of generic antiepileptic drug, Felbamate

Amneal Pharmaceuticals, LLC is pleased to announce that its generic Felbamate tablets are now available in 400 mg and 600 mg strengths. Amneal's latest First-to-Market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic drug Felbatol. Annual U.S. sales of Felbatol® are $43.7 million according to January 2011 IMS Health market data.

19 Sep 2011

Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that top-line data from part one of a two-part Phase 1 study of SPI-1620 in combination with docetaxel was presented in an oral presentation at the 12th International Conference on Endothelin, held in Cambridge, United Kingdom, from September 11-14, 2011. Part one of the study has been completed, while part two is ongoing.

19 Sep 2011

UMF sponsors second annual Hygiene Specialist Excellence award

Environmental Services Managers are encouraged to nominate the housekeeper of their choice for the second annual Hygiene Specialist Excellence award, which is sponsored by UMF Corporation, developer of the PerfectCLEAN Infection Prevention System.

19 Sep 2011

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

19 Sep 2011

Alkermes establishes business operations in Ireland

Alkermes plc today announced the establishment of its corporate operations in Ireland, with new headquarters located in Dublin. The company, including its headquarters and operations in Athlone, County Westmeath, has more than 450 employees based in Ireland and more than 1,200 employees worldwide.

19 Sep 2011

NeuroVive, Selcia sign research collaboration agreement to develop new mitochondrial drugs

UK-based contract research organisation Selcia Limited and Swedish drug development company NeuroVive Pharmaceutical AB have signed a significant research collaboration agreement to develop new medicines and drug compounds targeting mitochondrial physiology and pathophysiology.

19 Sep 2011

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced that data about hypoparathyroidism will be presented at the 2011 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego, CA, September 16-20, 2011.

19 Sep 2011

Two newer Type 2 diabetes drugs could be linked to increased risk of pancreatic cancer

Two newer drugs used to treat Type 2 diabetes could be linked to a significantly increased risk of developing pancreatitis and pancreatic cancer, and one could also be linked to an increased risk of thyroid cancer, according to a new UCLA study.

19 Sep 2011

New report finds decline in clinical trial recruitment for autoimmune disorders

The number of patients recruited to clinical trials for autoimmune disorders has waned in the last ten years, according to a new report available on companiesandmarkets.com.

19 Sep 2011

MDC Partners acquires majority stake in Concentric Pharma Advertising

MDC Partners announced today that they have acquired a majority stake in leading healthcare and pharma advertising and marketing agency, Concentric Pharma Advertising.

17 Sep 2011

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

Novartis announced today positive results of the first pivotal Phase III trial of ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease. The results, presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, showed all primary and secondary endpoints of the study were met.

17 Sep 2011

Supplement in USA Today highlights global NTD eradication efforts

This supplement (.pdf) by Mediaplanet, distributed in the September 15 issue of USA Today in select cities nationwide, examines the latest programs dedicated to eradicating neglected tropical diseases (NTDs) worldwide.

17 Sep 2011

Millennium ranked fifth among best biopharmaceutical companies in the world

Millennium: The Takeda Oncology Company today announced that Science magazine has named it among the best biopharmaceutical companies in the world for the fourth consecutive year. Each year Science conducts a survey to determine the top employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries worldwide.

17 Sep 2011

Additional data on safety, tolerability of Cempra's solithromycin to be presented at 51st ICAAC

Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago. The abstracts provide additional data that demonstrate the safety and routes of administration of CEM-101, a new generation macrolide.

17 Sep 2011

InNexus Biotechnology announces incentive stock options

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announces that it has, effective August 26, 2011, granted incentive stock options to purchase an aggregate of 1,068,683 common shares without par value in the capital of the Company to certain persons who are either a director, officer, employee or consultant of the Company.

17 Sep 2011

Wolters Kluwer Pharma Solutions leases 70,000-square-foot space in Phoenix

Wolters Kluwer Pharma Solutions, a leading provider of scientific information and analytics to pharmaceutical and healthcare professionals, today announced the signing of an 8-year lease on 70,000 square feet of new office space in the Biltmore Financial Center office park in Phoenix, AZ.

17 Sep 2011